Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$3.30M$3.30M−24.1% vs Q3 2024 Net Income-$14.61M-$14.61MN/M vs Q3 2024 EPS Diluted-$0.12-$0.12N/M vs Q3 2024 Operating Income-$17,149,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,955,000N/M Margins · derivedOperating margin-519.8%−278.9 pt vs Q3 2024
Net margin-443.0%−268.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end